Angiogenesis, Exudation, and Degeneration February 7, 2015 Mandarin Oriental, Miami, Florida
|
|
- Millicent Potter
- 8 years ago
- Views:
Transcription
1 Angiogenesis, Exudation, and Degeneration 2015 February 7, 2015 Mandarin Oriental, Miami, Florida Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director: Carmen A. Puliafito, MD, MBA PROGRAM Subject to Change Saturday, February 7, :00 am Registration and Continental Breakfast 7:55 Welcome and Overview Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA Session I: Dry Age-Related Macular Degeneration Moderator: Philip J. Rosenfeld, MD, PhD 8:00 AMD Genetics-Functional Impact of Common and Rare Variants Johanna M. Seddon, MD, SCM 8:10 Subcellular Basis of How RPE Autofluorescence Varies in AMD Christine A. Curcio, PhD, FARVO 8:20 Complement and the Extracellular Matrix in Early Macular Degeneration Eric Pierce, MD, PhD 8:30 Determination of Extracellular Matrix Changes in the Inner Choroid of Subjects with Age-Related Macular and Its Relationship with Rod Dysfunction Karl G. Csaky, MD, PhD 8:40 Update on Reticular Pseudodrusen (Subretinal Drusenoid Deposits) Richard Spaide MD 8:50 The Association Between Reticular Pseudodrusen and Delayed Dark Adaptation? Catherine Cukras, MD
2 9:00 Widefield OCT Imaging: AMD, Choroidal Thickness, and Reticular Pseudodrusen Karen Schaal, MD 9:10 GA Progression in the AREDS2 Emily Y. Chew, MD 9:20 Outcome Variables in AMD Clinical Trials Frederick Ferris, MD 9:30 OCT Angiography in AMD Nadia Waheed, MD Session II: Neovascular AMD I: Does Anti-VEGF Therapy Induce Macular Atrophy? Moderators: Philip J. Rosenfeld, MD, PhD and Carmen Puliafito MD, MBA Panelists: Daniel Martin, MD; Glenn J. Jaffe, MD; Usha Chakravarthy, MD; SriniVas R. Sadda, MD; K. Bailey Freund, MD; and Giovanni Staurenghi, MD 9:40 CATT: Beyond Choice of Drug Daniel Martin, MD 9:50 Retina Morphology/Visual Acuity Correlations in the Second Year of CATT and Beyond Glenn J. Jaffe, MD 10:00 Atrophy, Geographic Atrophy, and Lesion Involution in the IVAN Study Usha Chakravarthy, MD 10:10 Macular Atrophy in the HARBOR Study SriniVas R. Sadda, MD 10:20 Geographic Atrophy in Patients Receiving Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration K. Bailey Freund, MD 10:30 Geographic Atrophy and Anti VEGF Treatment: Is There a Correlation? Giovanni Staurenghi, MD 10:40 Panel Discussion
3 Session III: Emerging Technologies and Therapies in AMD Moderator: Carmen A. Puliafito, MD, MBA 10:50 Top Innovations in Retina - A VC Perspective Emmett Cunningham 11:00 Using Mobile Technology for Global Photographic Screening and Treatment of Retinal Diseases Mark S. Blumenkranz, MD 11:10 Lampalizumab Clinical Trial Update Carl D. Regillo, MD 11:20 Role of Genetics in the Growth Rate of GA Kang Zhang, MD, PhD 11:30 C3 Inhibition in AMD Philip J. Rosenfeld, MD, PhD 11:40 Geographic Atrophy: Teaching An Old Drug New Tricks Jayakrishna Ambati, MD 11:50 Nanosecond Laser Therapy for Drusen in Intermediate AMD Robyn Guymer, MD 12:00 The Rationale for Mitochondrial Targeted Therapeutics in Dry AMD Scott Cousins, MD Session IV: Stem Cells for Retinal Diseases Moderator: Wen-Hsiang Lee, MD, PhD 12:10 Safety and Technical Aspects of Subretinal Injection for Delivery of Cell and Gene Therapy Steven Schwartz, MD 12:20 Retinal Transplantation of ips Cell-Derived RPE Sheet for Age-Related Macular Degeneration Masayo Takahashi, MD, PhD 12:30 h-esc Derived RPE Transplantation for Atrophic AMD and Stargardt Disease Ninel Z. Gregori, MD
4 12:40 Phase I/II Study of the Safety and Preliminary Efficacy of Human Neural Stem Cells (HuCNS-SC) in AMD with Geographic Atrophy: Interim Analysis Theodore Leng, MD, MS 12:50 Cell Therapy for Atrophic Age Related Macular Degeneration: CNTO Year Phase 1/2 Results Allen C. Ho, MD 1:00 Embryonic Stem Cell-Derived RPE: The California Project David R. Hinton, MD 1:10 Lunch Session V: Neovascular AMD II Moderator: Philip J. Rosenfeld, MD, PhD 2:00 Effect of Anti-VEGF Therapy on Choroidal Thickness Stephan Michels, MD, MBA 2:10 Why Night Vision Matters in AMD: Lessons from HARBOR Ronald Frenkel, MD 2:20 How Did PEDs Respond in the HARBOR Study? Elias Reichel, MD 2:30 Efficacy of Intravitreal Injection of Conbercept in Polypoidal Choroidal Vasculopathy Xiaoxin Li, MD 2:40 Conbercept in Neovascular AMD Patients with Very Poor Visual Acuity: The LAMP Trial Xiaoyan Ding, M.D. Ph.D 2:50 Intravitreal Ziv-Aflibercept for the Treatment of Neovascular AMD Michel E. Farah, MD 3:00 Anti-VEGF DARPin (abicipar pegol) in Neovascular AMD David M. Brown, MD, FACS
5 Session VI: Neovascular AMD III Moderator: Jaclyn L. Kovach, MD 3:10 Oral VEGF Inhibition for Neovascular AMD Jason S. Slakter, MD 3:20 VEGF Inhibition with Encapsulated Cell Technology Peter K. Kaiser, MD 3:30 Continuous VEGF Suppression and Anti-VEGF Gene Therapy Thomas W. Chalberg, PhD 3:40 Anti-PDGF Pretreatment in AMD - Results of a Pilot Study Evaluating VEGF/PDGF Crosstalk Pravin U. Dugel, MD 3:50 Combined Anti-PDGF/Anti-VEGF Therapy in Neovascular AMD Jeffrey S. Heier, MD 4:00 Update on Squalamine Eye Drops for Neovascualar AMD Lawrence J. Singerman, MD, FACS, FICS 4:10 Radiation for Wet AMD: The European Clinical Experience and STAR Trial Update Darius M. Moshfeghi, MD Session VI: Chorioretinal, Vitreomacular, and Venous Occlusive Diseases Moderator: Harry W. Flynn, Jr., MD 4:20 Chronic Central Serous Chorioretinopathy in Elderly Patients Lawrence A. Yannuzzi, MD 4:30 MacTel Project Update Martin Friedlander, MD, PhD 4:40 CNTF for Optic Nerve Disease Thomas Albini, MD 4:50 Current Clinical Trials for Hereditary Chorioretinal Degenerations Byron L. Lam, MD 5:00 Peripheral Retinal Vascular Findings in Adults and Children Michael T. Trese, MD
6 5:10 Update on Aflibercept for BRVO David S. Boyer, MD 5:20 OCT Angiography of Diabetes Jay S. Duker, MD 5:30 DRCR.net Update: Protocol T Harry W. Flynn, Jr., MD Session VII: Diabetes Moderator: Andrew A. Moshfeghi, MD, MBA 5:40 RIDE and RIDE: An Update on Ranibizumab for Diabetic Retinopathy Baruch D. Kuppermann, MD, PhD 5:50 Update on Aflibercept for DME Diana V. Do, MD 6:00 Ozurdex for Diabetic Macular Edema: The ORVO Study Peter A. Campochiaro, MD 6:10 Promising Therapies in Development for DME: TIE-2 Activator, Integrin Peptide, and Vascular Adhesion Protein-1 Quan Dong Nguyen, MD, MSc 6:20 Adjourn/Cocktail Reception
Angiogenesis, Exudation, and Degeneration 2014. February 8, 2014 Mandarin Oriental, Miami, Florida
Angiogenesis, Exudation, and Degeneration 2014 February 8, 2014 Mandarin Oriental, Miami, Florida Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director:
More informationAngiogenesis, Exudation, and Degeneration 2016. February 6, 2016 Mandarin Oriental, Miami, FL
Angiogenesis, Exudation, and Degeneration 2016 February 6, 2016 Mandarin Oriental, Miami, FL Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director: Carmen
More informationAngiogenesis, Exudation, and Degeneration 2016. February 6, 2016. Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2016 February 6, 2016 Bascom Palmer Eye Institute Miami,florida Sponsored by the University of Miami Miller School of Medicine BASCOM PALMER EYE INSTITUTE Angiogenesis,
More informationAPRIL 8th 2016 Therapy
APRIL 8th 2016 Therapy 09.00-10.00 SESSION 1: Age-related Macular Degeneration Moderators: S. Sadda, D. Sarraf, K. Bailey Freund, E. Souied 09.00-09.15 Prospective SD OCT Analysis of PED Associated with
More informationICG IMAGING FOR EXUDATIVE ARMD
ICG IMAGING FOR EXUDATIVE ARMD MARK H. NELSON, MD MBA WINSTON-SALEM, NC ASRS INSTRUCTION COURSE AUGUST 24, 2011 FINANCIAL DISCLOSURE Novartis Pharmaceutics, Incorporated Consultant, Grant Recipient Heidelberg
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationOhr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationCompleted Clinical Research Trials Prema Abraham, M.D.
Completed Clinical Research Trials Prema Abraham, M.D. AMD Studies 2010 Present Principal Investigator: A Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous
More informationAn Informational Guide to CENTRAL RETINAL VEIN OCCLUSION
Science of CRVO www.scienceofcrvo.org An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION This brochure will guide you in understanding CRVO and the treatment options available to prevent vision loss.
More informationGeographic Atrophy: The Advanced Form of Dry AMD
Age-related macular degeneration (AMD) is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such
More informationWhy Does Anti VEGF Treatment Fail in Age Related Macular Degeneration (AMD)
Original Article Why Does Anti VEGF Treatment Fail in Age Related Macular Degeneration (AMD) Manoj S. MS Aim: To evaluate eyes with AMD that responded poorly to anti VEGF therapy and study reasons for
More informationDiabetes & blindness. due to DME BLINDNESS IN EUROPE
Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million
More informationAge- Related Macular Degeneration
Age- Related Macular Degeneration Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the United States. It is caused by damage to a localized area of the central retina called
More informationACTVE INTERVENTIONAL CLINICAL TRIALS - 03/01/2015. Principal Investigator Study Title and Sponsor Study Description
Cornea and External Disease Service Li, Jennifer A Prospective, Multicenter Post-Approval Study (PAS) of VisionCare s Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral
More informationTrends in Ophthalmology a Market Perspective. Matthias Karl, Michael Kempe
Trends in Ophthalmology a Market Perspective Matthias Karl, Michael Kempe 30.04.2013 Agenda 1 2 3 4 Role of Optical Technologies in Ophthalmology Demands of the Market - Trends in the Application Implications
More informationThe Macula Society 34 rth Annual Meeting SCIENTIFIC PROGRAM
The Macula Society 34 rth Annual Meeting Boca Raton, Florida March 9-12, 2011 SCIENTIFIC PROGRAM 6:45 a.m. Young Member Mentor Lecture Key Note Speaker: Dr. William Mieler The 8 minutes allotted time for
More informationAvastin (Bevacizumab) Intravitreal Injection
Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as
More informationCharles C Wykoff, David M Brown, Maria E Maldonado, Daniel E Croft. Clinical science
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) Charles C Wykoff, David M Brown, Maria
More informationAge-Related Macular Degeneration. K. Bailey Freund, M.D. James M. Klancnik, Jr., M.D. Lawrence A. Yannuzzi, M.D. Bruce Rosenthal, O.D.
Age-Related Macular Degeneration K. Bailey Freund, M.D. James M. Klancnik, Jr., M.D. Lawrence A. Yannuzzi, M.D. Bruce Rosenthal, O.D. Contents Introduction 5 Anatomy of the Eye 6 The Eye 7 The Retina 9
More informationWe are on WHAT ARE THE RISK FACTORS FOR MACULAR DEGENERATION?
We are on WHAT ARE THE RISK FACTORS FOR MACULAR DEGENERATION? Age Being 60 years of age and older Race Whites are much more likely to lose vision from AMD than Blacks Gender Women tend to be at greater
More informationRetinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease
Retinal Imaging Biomarkers for Early Diagnosis of Alzheimer s Disease Eleonora (Nora) Lad, MD, PhD Assistant Professor of Ophthalmology, Vitreoretinal diseases Duke Center for Macular Diseases Duke University
More informationIntroduction. Stephan Michels, MD, MBA, is a professor at the University of Zurich and vice chair at Triemli Hospital in Zurich, Switzerland.
Introduction A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology to participate in a roundtable discussion regarding protocols for the treatment of diabetic
More informationCommissioning better eye care
Commissioning better eye care Clinical commissioning guidance from The College of Optometrists and The Royal College of Ophthalmologists Age-related macular degeneration Version: 1 Published: 25 Nov 2013
More informationCurrent Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015
Central Retinal Vein Occlusion Hemi-Central Vein Occlusion Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015 Branch Retinal Vein Occlusion Ischemic vs. non-ischemic BRVO
More information16th ESASO Retina Academy Programme
16th ESASO Retina Academy Programme 23 25 June 2016, Estoril, Portugal THURSDAY, 23 JUNE 2016 14:00 Registration opens Congress hall 14:00 17:30 Poster Hanging 14:00 IMAGING WORKSHOP Room B Imaging Companies
More informationRetinal Update: November 2009 - March 2010
Retinal Update: November 2009 - March 2010 Diabetic Retinopathy Macular Degeneration: Age-related macular degeneration Macular Degeneration: Choroidal neovascularization Macular Disease: Central serous
More informationLong-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
Long-term Outcomes of Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE David M. Brown, MD, 1,x Quan Dong Nguyen, MD, MSc, 2,x Dennis M. Marcus, MD, 3 David
More informationIR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema. September 28, 2013
IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema September 28, 2013 Safe Harbor Statement This presentation includes forward-looking statements that involve risks and uncertainties
More information16th ESASO Retina Academy Programme
16th ESASO Retina Academy Programme 23 25 June 2016, Estoril, Portugal THURSDAY, 23 JUNE 2016 14:00 Registration opens Congress hall 14:00 17:30 Poster display 14:00 17:30 IMAGING WORKSHOP Room B Technical
More informationRadiation Therapy for Small Choroidal Neovascularization in Age-related Macular Degeneration
Radiation Therapy for Small Choroidal Neovascularization in Age-related Macular Degeneration Hideaki Matsuhashi,* Yasuko Noda,* Daisuke Takahashi* and Yasushi Mariya Departments of *Ophthalmology; Radiology,
More informationA Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Purpose This study is currently patients. Verified by Neurotech Pharmaceuticals March 2007 Sponsored
More informationINFORMATION ON DARC: THE DIGITAL ANGIOGRAPHY READING CENTER
INFORMATION ON DARC: THE DIGITAL ANGIOGRAPHY READING CENTER 1 DIGITAL ANGIOGRAPHY READING CENTER Chairman/Medical Director Jason S. Slakter, M.D. Clinical Professor of Ophthalmology NYU School of Medicine
More informationAmerican Society of Retina Specialists Retinal Innovation Forum Abstracts
Genentech Genentech Research in Ophthalmology Gary Sternberg, MD At Genentech we focus our research and development practice on discovering and developing new medicines for unmet medical needs. The Genentech
More informationVisual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy
Medical Care for the Elderly Visual Disorders in Middle-Age and Elderly Patients with Diabetic Retinopathy JMAJ 46(1): 27 32, 2003 Shigehiko KITANO Professor, Department of Ophthalmology, Diabetes Center,
More informationRetina InSight Volume 1 Issue 1 Fall 2014
Retina InSight Volume 1 Issue 1 Fall 2014 Welcome to our GHRRF Newsletter! We are passionate about fighting blindness through cutting edge research. The purpose of this newsletter is to share information
More informationIntroduction Houston Retina Associates
1 2 Introduction This book was written by Houston Retina Associates to provide our patients with basic knowledge about retinal anatomy, an introduction to some of the diagnostic tests and treatments used
More informationTHE NEW ENGLAND OPHTHALMOLOGICAL SOCIETY FOR NURSING AND ALLIED HEALTH PERSONNEL. December 13, 2013 INNOVATIONS IN OPHTHALMIC CARE
THE NEW ENGLAND OPHTHALMOLOGICAL SOCIETY THE 24 th ANNUAL OPHTHALMIC MEETING FOR NURSING AND ALLIED HEALTH PERSONNEL December 13, 2013 INNOVATIONS IN OPHTHALMIC CARE REGISTER HERE: http://www.neos-eyes.org/app/attendee/index.cfm?id=ljfco1v
More informationPhotographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Photographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-Related Macular Degeneration Treatments Trials Juan E. Grunwald, MD, 1,2 Ebenezer Daniel, MBBS, PhD, 1,2 Gui-shuang
More informationSpectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling.
Spectral domain OCT used to view and quantify choroidal vascular congestion in new subretinal fluid following scleral buckling. Robert Gizicki MD, Mohamed Haji, Flavio Rezende Retina Service, Hôpital Maisonneuve-Rosemont,
More informationGenetic Testing for Macular Degeneration
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information1981-1982 Ophthalmic Consultants Northwest, Seattle, Washington Retinal and vitreous consultation and surgery
EDUCATION Richard S. Munsen Jr., MD University of Washington Eye Institute HMC Box 359608, 325 Ninth Ave, Seattle WA 98104-2499 (206) 744-2020 for patient appointments, Fax (206) 897-4320 Academic phone
More informationAffiliation : ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO). AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO)
Curriculum Vitae Federico Ricci, MD Name: Federico Ricci, MD. Titolo Accademico /Title: Professore Aggregato di Oftalmologia / Aggregate Professor of Ophthalmology Direttore UOSD Patologie Retiniche [Centro
More informationFrom an inauspicious start several years ago, the use
The Current Status of Stem Cells in Ophthalmology By Irv Arons From an inauspicious start several years ago, the use of stem cells (SCs) in the treatment of several ocular and retinal diseases has picked
More informationICOP 2011 OXFORD UK REPORT ON THE INTERNATIONAL CONFERENCE ON OPHTHALMIC PHOTOGRAPHY 2011
ICOP 2011 OXFORD UK REPORT ON THE INTERNATIONAL CONFERENCE ON OPHTHALMIC PHOTOGRAPHY 2011 Report compiled by: Rahila Bashir and the MEDICAL IMAGING UK Ltd conference team On September the 22 nd we saw
More informationNAVILAS Laser System Focal Laser Treatment for Diabetic Macular Edema - One Year Results of a Case Series
Send Orders for Reprints to reprints@benthamscience.net 48 The Open Ophthalmology Journal, 2013, 7, 48-53 Open Access NAVILAS Laser System Focal Laser Treatment for Diabetic Macular Edema - One Year Results
More information12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation
BJO Online First, published on April 10, 2014 as 10.1136/bjophthalmol-2013-304488 Clinical science 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab
More information5,500,000 Shares of Common Stock. Warrants to Purchase 2,750,000 Shares of Common Stock
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-199311 PROSPECTUS SUPPLEMENT (to Prospectus dated
More informationEye Department Baden-Baden. Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich. Ophthalmology specialists
E y e D e p a r t m e n t Prof. Dr. med. Frank Faude Dr. med. Susanne Faude Oxana Bräunlich Ophthalmology specialists Prof. Dr. med. Frank Faude Inpatient and outpatient treatment at the Stadtklinik Baden-Baden
More informationINTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE DETAILED TABLE
Proposed Disease Severity Level No apparent Mild Non- Proliferative Moderate Nonproliferative Severe Non- Proliferative Proliferative INTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE
More informationAcucela Inc. IR Meeting
Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening
More informationHow To Learn About Eye Care
Advance Program and Registration 2014 NAEPS Fall Scientific Meeting and 15th Annual Continuing Education Symposium September 26-27, 2014 Doubletree Hotel / 1616 Dodge Street / Omaha, NE 68102 Jointly provided
More informationMark S. Blumenkranz, MD
Scientific program Thursday FRIday, September 24 Thursday, September 23 Th u r s d a y, Se p t e m b e r 23 3:00 7:00 pm Registration 3:30 4:30 Symposium: The Impact of Electronic Health Records and PQRI
More informationRetina InSight Volume 2 Winter 2015/2016
Retina InSight Volume 2 Winter 2015/2016 News from the Greater Houston Retina Research Foundation RCH Retina Rangers Give Back at Houston VisionWalk 2015 Hearts were pounding and pulses racing at the 2015
More informationResults from the Age-Related Eye Disease Study
Results from the Age-Related Eye Disease Study Age-Related Eye Disease Study Table of Contents What is a Cataract?...4 What is Age-related Macular Degeneration?...4-6 Treatments...7 Results-Cataract...8
More informationAdvocating for Improved Treatment and Outcomes for Diabetic Macular Edema
Advocating for Improved Treatment and Outcomes for Diabetic Macular Edema A Report Based on an International Expert Summit Convened in Paris, June 2014 Acknowledgements This publication was supported by
More informationTHOMAS IRA MARGOLIS, M. D. OFFICE ADDRESS: BIRTH DATE: May 11, 1962 1500 Tilton Road PROFESSIONAL EXPERIENCE
THOMAS IRA MARGOLIS, M. D. OFFICE ADDRESS: BIRTH DATE: May 11, 1962 1500 Tilton Road Northfield, NJ 08225 PLACE OF BIRTH: Uniontown, PA 609-646-5200 FAX 609-646-9868 PROFESSIONAL EXPERIENCE RETINAL AND
More informationPreparing for ICD-10 Advance Preparation for Implementation Charles Brownlow, OD drbrownlow@pmi-eyes.com
Preparing for ICD-10 Advance Preparation for Implementation Charles Brownlow, OD drbrownlow@pmi-eyes.com International Classification of Diseases (ICD-9, ICD-10) Both include codes for all medical conditions,
More informationRetinal Detachments Mark E. Hammer, M.D. Ivan J. Suñer, M.D. Marc C. Peden, M.D.
Retinal Detachments Mark E. Hammer, M.D. Ivan J. Suñer, M.D. Marc C. Peden, M.D. What is a retinal detatchment? The retina is the light sensitive layer covering the inside of the back of the eye. It is
More informationOptical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration.
Imaging Optical Coherence Tomography Imaging and Quantitative Assessment for Monitoring Dry Age-related Macular Degeneration Albert J Augustin Head, Department of Ophthalmology, Staedtisches Klinikum Karlsruhe
More informationThis newest generation laser offers specific technological features and treatment options designed to substantially improve the retina laser therapy:
1 The latest generation of Quantel Medical Multispot Laser (Supra Scan 577) offers new technological features and treatment methods for improving retina laser therapy. Q uantel Medical Lasers give excellent
More informationNC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION
NC DIVISION OF SERVICES FOR THE BLIND POLICIES AND PROCEDURES VOCATIONAL REHABILITATION Section: E Revision History Revised 01/97; 05/03; 02/08; 04/08; 03/09; 05/09; 12/09; 01/11; 12/14 An individual is
More informationType 1 neovascularization with polypoidal lesions complicating dome shaped macula
DOI 10.1186/s40942-015-0008-5 CASE REPORT Open Access Type 1 neovascularization with polypoidal lesions complicating dome shaped macula Jonathan Naysan 1,2,3,4, Kunal K Dansingani 1,2,5, Chandrakumar Balaratnasingam
More informationAdvances in retinal implant technology
Advances in retinal implant technology Andrew Kuznetsov Freiburg i.br. 3 May 2012 Rhine-Waal University of Applied Sciences, Emmerich Strategies electronic implants (top-down) subretinal implants epiretinal
More informationAdult and Paediatric Retina (Vitreo-Retinal Surgery, Laser and Intravitreal Injection)
CV Name: Dr Loh Boon Kwang Specialty: General Ophthalmology and Cataract Surgery Subspecialty: Adult and Paediatric Retina (Vitreo-Retinal Surgery, Laser and Intravitreal Injection) Adult Retina Conditions
More information82 Gilbert Street, Adelaide, SA, 5000 82 Gilbert Street, Adelaide, SA, 5000 W +61 8 8104 5293 M +61 417 818 658 W +61 8 8104 5200 M +61 414 661 994
ASX RELEASE Ellex Medical Lasers Limited (ASX:ELX) Adelaide, Australia Date: 14 September 2015 Release: Immediate Topic: Ellex releases first case study results for 2RT at major tradeshow Adelaide, Australia,
More informationRanibizumab for Macular Edema following Central Retinal Vein Occlusion
for Macular Edema following Central Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study David M. Brown, MD, FACS, 1 Peter A. Campochiaro, MD, 2 Rishi P. Singh, MD, 3 Zhengrong
More informationClinical Applications of Optical Coherence Tomography in Ophthalmology
11 Clinical Applications of Optical Coherence Tomography in Ophthalmology Upender K. Wali and Nadia Al Kharousi College of Medicine and Health Sciences, Sultan Qaboos University Oman In Ophthalmology,
More informationDiabetic macular edema (DME) is the primary cause of
Retina Fully Software for Retinal Thickness in Eyes With Diabetic Macular Edema From Images Acquired by Cirrus and Spectralis Systems Joo Yong Lee, 1,2 Stephanie J. Chiu, 3 Pratul P. Srinivasan, 3 Joseph
More informationGet Your Eyes Examined
1 Vision Changes You may notice vision changes with aging. Many changes are common and can often be corrected. As you get older, you are at higher risk of age-related eye diseases and conditions. Get Your
More informationEye Diseases. 1995-2014, The Patient Education Institute, Inc. www.x-plain.com otf30101 Last reviewed: 05/21/2014 1
Eye Diseases Introduction Some eye problems are minor and fleeting. But some lead to a permanent loss of vision. There are many diseases that can affect the eyes. The symptoms of eye diseases vary widely,
More informationDiabetic Eye Screening Revised Grading Definitions
Diabetic Eye Screening Revised Grading Definitions Version 1.3, 1 November 2012 To provide guidance on revised grading definitions for the NHS Diabetic Eye Screening Programme Project/Category Document
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCase Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
Case Reports in Medicine Volume 2012, Article ID 134636, 4 pages doi:10.1155/2012/134636 Case Report Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis Lei Liu and Fiona
More informationAge-Related Eye Diseases and Conditions. See Well for a Lifetime
Age-Related Eye Diseases and Conditions See Well for a Lifetime Vision Changes You may notice vision changes with aging. Many changes are common and can often be corrected. As you get older, you are at
More informationProgram Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
More informationTucson Eye Care, PC. Informed Consent for Cataract Surgery And/Or Implantation of an Intraocular Lens
Tucson Eye Care, PC Informed Consent for Cataract Surgery And/Or Implantation of an Intraocular Lens INTRODUCTION This information is provided so that you may make an informed decision about having eye
More informationSOCT Copernicus HR Specification
Specification Light Source: SLED Central Wavelength: 850 nm Axial Resolution: 3 µm Transversal Resolution: 12-18 µm Scanning Speed: 52000 A-Scan per second A-Scan Resolution: 1024 points B-Scan Resolution:
More informationSTEM CELL FELLOWSHIP
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
More informationSample Letters and Emails for a Fundraising Letter Writing Campaign
Sample Letters and Emails for a Fundraising Letter Writing Campaign What you ll find in this packet: 1. Letter-writing instructions. 2. A sample letter and email for FFB s VisionWalk. 3. Samples of successful
More informationCARMEN A. PULIAFITO, M.D., M.B.A. DEAN, KECK SCHOOL OF MEDICINE OF THE UNIVERSITY OF SOUTHERN CALIFORNIA
CARMEN A. PULIAFITO, M.D., M.B.A. DEAN, KECK SCHOOL OF MEDICINE OF THE UNIVERSITY OF SOUTHERN CALIFORNIA Dr. Carmen A. Puliafito was recently reappointed to a second term as Dean of the Keck School of
More informationPeter E. Liggett, M.D. 2200 Whitney Avenue-Suite 300 Hamden, CT 06518 Tel: (203) 288-2020 Fax: (203) 288-2470
Liggett Newsletter 11.10.05 FINAL 11/10/05 1:02 PM Page 1 N E R A New England Retina Associates N E R A New England Retina Associates 2200 Whitney Avenue-Suite 300 Hamden, CT 06518 Tel: (203) 288-2020
More informationPlease allow us to welcome you to our practice. Our first priority is to provide you with the best care possible.
PAUL L. TREGER, M.D. RANDALL CONRAD, O.D. GLENN B. COOK, M.D., PhD TARA BROWN, M.D. 7877 PARKWAY DRIVE SUITE 100 - LA MESA, CA 91942 619.286.3711 FAX 619.286.2184 Dear Please allow us to welcome you to
More information22/02/2015. Possible causes. Decisions decisions decisions. Challenging eye and ear conditions at underwriting and claim stage Dr Maritha van der Walt
Challenges Underwriting symptoms rather than conditions- tinnitus, vertigo, blurred vision Requests for narrower rather than broad exclusions and consequences Pre existing condition and unrelated claims
More informationAlexandria Fairfax Sterling Leesburg 703-931-9100 703-573-8080 703-430-4400 703-858-3170
DIABETIC RETINOPATHY www.theeyecenter.com This pamphlet has been written to help people with diabetic retinopathy and their families and friends better understand the disease. It describes the cause, symptoms,
More informationCorporate Medical Policy
Corporate Medical Policy Intravitreal Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravitreal_implant 11/2010 6/2015 6/2016 6/2015 Description of Procedure or Service
More informationVitreo-Retinal and Macular Degeneration Frequently Asked Questions
Vitreo-Retinal and Macular Degeneration Frequently Asked Questions What is a Vitreo-Retinal specialist? Retinal specialists are eye physicians and surgeons who focus on diseases in the back of the eye
More information04/03/2015. EMR Documentation and Compliance: The Retina Point of View. Financial Disclosure. Financial Disclosure
EMR Documentation and Compliance: The Retina Point of View William T. Koch, COA, COE, CPC The Retina Institute Kirk A. Mack, COMT, COE, CPC, CPMA Corcoran Consulting Group Financial Disclosure William
More informationDexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Issued: July 2011 guidance.nice.org.uk/ta229 NICE has accredited the process used by the Centre
More informationLiterature Search on The Prevalence of Visual Disorders by Age Group in Older People
Literature Search on The Prevalence of Visual Disorders by Age Group in Older People Aggressive Research Intelligence Facility West Midlands Health Technology Assessment Collaboration October 2006 For
More informationREGISTRATION FORM Continuing Medical Education #157744
REGISTRATION FORM Continuing Medical Education #157744 35th ANNUAL ALAMO CITY OPHTHALMOLOGY CLINICAL CONFERENCE Saturday, April 11, 2015 UT Health Science Center Pestana Lecture Hall 3.104 7703 Floyd Curl
More informationA Modified Semiautomatic Method for Measurement of Hyperfluorescence Area in Fluorescein Angiography
A Modified Semiautomatic Method for Measurement of Hyperfluorescence Area in Fluorescein Angiography Khalil Ghasemi Falavarjani, MD 1 Hanieh Mohammadreza, MSc 2 Sedigheh Marjaneh Hejazi, PhD 3 Masood Naseripour,
More information2014 San Diego MEETING AT A GLANCE AUGUST 9 13
2014 San Diego MEETING AT A GLANCE AUGUST 9 13 EVENT LOCATIONS General Sessions Retina Case Conference Continental Breakfasts & Breaks Lunches Sapphire Ballroom 4th floor Sapphire Ballroom Indigo Ballroom
More informationOptic Disc Drusen. Normal Enlarged view of Optic Disc. Lumpy Appearance of Optic Disc. Optic Disc Drusen With Drusen
Optic Disc Drusen Your doctor has diagnosed you with optic disc drusen. Optic disc drusen are abnormal deposits of protein-like material in the optic disc the front part of the optic nerve. We do not know
More informationmacrophage Interaction and Photoplasia of Patients
CLINIC FOR OPHTHALMOLOGY UNIVERSITY OF LÜBECK DIRECTOR: PROF. DR. SALVATORE GRISANTI PATHOGENESIS OF AGE RELATED MACULAR DEGENERATION (AMD) Immunohistochemical evaluation of the macrophage activation pattern
More informationEye and Vision Care in the Patient-Centered Medical Home
1505 Prince Street, Alexandria, VA 22314 (703) 739-9200200 FAX: (703) 739-9497494 Eye and Vision Care in the Patient-Centered Medical Home The Patient Centered Medical Home (PCMH) is an approach to providing
More informationGap in Diagnosis of AMD
Disclosures New Methods in Diagnosing AMD Steven Ferrucci, OD, FAAO Chief, Sepulveda VA Professor, SCCO Speakers bureau/advisory board: Alcon Allergan Macula Risk VSP MacuLogix Reichert Technologies TradiDonal
More informationDepartment of Ophthalmology
OUTCOMES Division of Medicine Department of Ophthalmology About Cleveland Clinic Florida Cleveland Clinic Florida s medical staff are dedicated physicians who have joined the clinic as salaried doctors
More informationPreparing for laser treatment for diabetic retinopathy and maculopathy
Preparing for laser treatment for diabetic retinopathy and maculopathy This leaflet sets out to answer the questions people with diabetic retinopathy commonly ask about laser treatment. You might want
More informationCURRICULUM VITAE David G. Miller, MD
CURRICULUM VITAE OFFICE ADDRESSES Retina Associates of Cleveland, Inc. 3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122 14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107 18660 Bagley Road,
More information